Leader Biomedical’s OssGro® and Ossfinity® line of synthetic bone grafts are produced with MBCP™ Technology, a proprietary method for producing high quality synthetic bone grafts composed of 60% HA and 40% βTCP. Unlike other bulk production methodologies, this process relies on a sophisticated process of synthesis with several heating steps.
Ossfinity® combines OssGro® granules and an absorbable hydrogel to create a putty, which acts as a carrier for rapid vascularisation and mineralisation.
- Comes in a syringe for easy handling
- Easily used to different grafting sites
- Hydrogel ensures both containment and structural integrity
- Superior handling characteristics
There are no safety concerns or natural constraints to the availability of synthetic bone grafts. Synthetic bone grafts have proven to be an excellent alternative to human bone, especially when used in conjunction with bone marrow or proline-rich proteins (PRPs) to add osteoinductive properties to the graft.